Skip to main content

Advertisement

SpringerLink
Log in

Epidemiology and Importance of Renal Dysfunction in Heart Failure Patients

  • Epidemiology of Heart Failure (J Butler, Section Editor)
  • Published:
Current Heart Failure Reports Aims and scope Submit manuscript

Abstract

Renal dysfunction (RD) is a frequent comorbid condition and a major determinant of outcomes in patients with heart failure (HF). It is likely that the etiology of RD in patients with HF is much more complex than we first thought and represents a matrix of independent, albeit interacting, pathophysiological pathways with effects on both the kidney and the heart that share a common denominator: aging and inflammation. Renal dysfunction in HF has been attributed, among others, to biochemical, hormonal, and hemodynamic factors, coupled with pharmacological interventions. Regardless of the cause, the development of RD or worsening renal function is common in patients with HF, and is associated with increased morbidity and mortality. There is increasing evidence, however, that transient increases in creatinine in the setting of acute HF are not prognostically important, whereas persistent deterioration does portend a higher mortality in this patient population. In addition, congestion seems to play an important role in the course of renal deterioration, and the combination of congestion and worsening renal function is the most significant clinical prognosticator in HF patients. This review aims to provide an update on the epidemiology and prognostic significance of RD in HF patients, in both the acute and the chronic setting.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. Cole RT, Masoumi A, Triposkiadis F, Giamouzis G, Georgiopoulou V, Kalogeropoulos A, et al. Renal dysfunction in heart failure. Med Clin N Am. 2012;96:955–74.

    Article  PubMed  CAS  Google Scholar 

  2. Giamouzis G, Kalogeropoulos A, Georgiopoulou V, Laskar S, Smith AL, Dunbar S, et al. Hospitalization epidemic in patients with heart failure: risk factors, risk prediction, knowledge gaps, and future directions. J Card Fail. 2011;17:54–75.

    Article  PubMed  Google Scholar 

  3. Cleland JG, Carubelli V, Castiello T, Yassin A, Pellicori P, Antony R. Renal dysfunction in acute and chronic heart failure: prevalence, incidence and prognosis. Heart Fail Rev. 2012;17:133–49.

    Article  PubMed  CAS  Google Scholar 

  4. Udani SM, Koyner JL. The effects of heart failure on renal function. Cardiol Clin. 2010;28:453–65.

    Article  PubMed  Google Scholar 

  5. Giamouzis G, Butler J, Triposkiadis F. Renal function in advanced heart failure. Congest Heart Fail. 2011;17:180–8.

    Article  PubMed  CAS  Google Scholar 

  6. Ronco C, Haapio M, House AA, Anavekar N, Bellomo R. Cardiorenal syndrome. J Am Coll Cardiol. 2008;52:1527–39.

    Article  PubMed  Google Scholar 

  7. • Triposkiadis F, Starling RC, Boudoulas H, Giamouzis G, Butler J. The cardiorenal syndrome in heart failure: cardiac? renal? syndrome? Heart Fail Rev. 2012;17:355–66. This is the first paper to question the existence of the “Cardiorenal Syndrome”. Based on several well-defined arguments, the authors present why they believe that dissecting one of the multiple bidirectional associations in HF and constructing the so-called cardiorenal syndrome is not justified pathophysiologically.

    Article  PubMed  Google Scholar 

  8. Padeletti L, Innocenti L, Paoletti Perini A, Gronda E. Arrhythmic complication in cardiorenal syndrome. Heart Fail Rev. 2011;16:569–73.

    Article  PubMed  Google Scholar 

  9. El Nahas M. Cardio-kidney-damage: a unifying concept. Kidney Int. 2010;78:14–8.

    Article  PubMed  Google Scholar 

  10. •• Smilde TD, van Veldhuisen DJ, Navis G, Voors AA, Hillege HL. Drawbacks and prognostic value of formulas estimating renal function in patients with chronic heart failure and systolic dysfunction. Circulation. 2006;114:1572–80. This is the first well-designed study to validate three commonly used formulas estimating glomerular filtration rate (GFR) with true GFR in HF patients. Furthermore, the authors compared the prognostic value of these formulas for cardiovascular outcome with that of true GFR.

    Article  PubMed  Google Scholar 

  11. Shenkman HJ, Zareba W, Bisognano JD. Comparison of prognostic significance of amino-terminal pro-brain natriuretic Peptide versus blood urea nitrogen for predicting events in patients hospitalized for heart failure. Am J Cardiol. 2007;99:1143–5.

    Article  PubMed  CAS  Google Scholar 

  12. • Filippatos G, Rossi J, Lloyd-Jones DM, Stough WG, Ouyang J, Shin DD, et al. Prognostic value of blood urea nitrogen in patients hospitalized with worsening heart failure: insights from the Acute and Chronic Therapeutic Impact of a Vasopressin Antagonist in Chronic Heart Failure (ACTIV in CHF) study. J Card Fail. 2007;13:360–4. This is the first study that evaluated the association between baseline blood urea nitrogen (BUN) and clinical outcomes in patients admitted for ADHF, using a post-hoc analysis of the ACTIV in CHF trial, showing that higher baseline BUN is a powerful predictor of increased postdischarge mortality in patients hospitalized for HF, even in the absence of severe renal failure.

    Article  PubMed  Google Scholar 

  13. Cauthen CA, Lipinski MJ, Abbate A, Appleton D, Nusca A, Varma A, et al. Relation of blood urea nitrogen to long-term mortality in patients with heart failure. Am J Cardiol. 2008;101:1643–7.

    Article  PubMed  CAS  Google Scholar 

  14. Schrier RW. Blood urea nitrogen and serum creatinine: not married in heart failure. Circ Heart Fail. 2008;1:2–5.

    Article  PubMed  CAS  Google Scholar 

  15. Kazory A. Emergence of blood urea nitrogen as a biomarker of neurohormonal activation in heart failure. Am J Cardiol. 2010;106:694–700.

    Article  PubMed  CAS  Google Scholar 

  16. Lin HJ, Chao CL, Chien KL, Ho YL, Lee CM, Lin YH, et al. Elevated blood urea nitrogen-to-creatinine ratio increased the risk of hospitalization and all-cause death in patients with chronic heart failure. Clin Res Cardiol Of J German Cardiac Soc. 2009;98:487–92.

    Article  CAS  Google Scholar 

  17. Perez-Calvo JI, Ruiz-Ruiz FJ, Carrasco-Sanchez FJ, Morales-Rull JL, Manzano-Fernandez S, Galisteo-Almeda L, et al. Prognostic value of serum cystatin C and N-terminal pro b-type natriuretic peptide in patients with acute heart failure. Eur J Intern Med. 2012;23:599–603.

    Article  PubMed  CAS  Google Scholar 

  18. Manzano-Fernandez S, Boronat-Garcia M, Albaladejo-Oton MD, Pastor P, Garrido IP, Pastor-Perez FJ, et al. Complementary prognostic value of cystatin C, N-terminal pro-B-type natriuretic Peptide and cardiac troponin T in patients with acute heart failure. Am J Cardiol. 2009;103:1753–9.

    Article  PubMed  CAS  Google Scholar 

  19. Lassus J, Harjola VP, Sund R, Siirila-Waris K, Melin J, Peuhkurinen K, et al. Prognostic value of cystatin C in acute heart failure in relation to other markers of renal function and NT-proBNP. Eur Heart J. 2007;28:1841–7.

    Article  PubMed  CAS  Google Scholar 

  20. Alehagen U, Dahlstrom U, Lindahl TL. Cystatin C and NT-proBNP, a powerful combination of biomarkers for predicting cardiovascular mortality in elderly patients with heart failure: results from a 10-year study in primary care. Eur J Heart Fail. 2009;11:354–60.

    Article  PubMed  CAS  Google Scholar 

  21. Lassus J, Harjola VP. Cystatin C: a step forward in assessing kidney function and cardiovascular risk. Heart Fail Rev. 2012;17:251–61.

    Article  PubMed  CAS  Google Scholar 

  22. Wen Z, Cai M, Mai Z, Chen Y, Geng D, Wang J. Protection of renal impairment by angiotensin II type 1 receptor blocker in rats with post-infarction heart failure. Ren Fail. 2013;35:766–75.

    Article  PubMed  CAS  Google Scholar 

  23. Coresh J, Wei GL, McQuillan G, Brancati FL, Levey AS, Jones C, et al. Prevalence of high blood pressure and elevated serum creatinine level in the United States: findings from the third National Health and Nutrition Examination Survey (1988–1994). Arch Intern Med. 2001;161:1207–16.

    Article  PubMed  CAS  Google Scholar 

  24. Calhoun DA, Jones D, Textor S, Goff DC, Murphy TP, Toto RD, et al. Resistant hypertension: diagnosis, evaluation, and treatment: a scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research. Circulation. 2008;117:e510–26.

    Article  PubMed  Google Scholar 

  25. Shlipak MG, Fried LF, Cushman M, Manolio TA, Peterson D, Stehman-Breen C, et al. Cardiovascular mortality risk in chronic kidney disease: comparison of traditional and novel risk factors. JAMA J Am Med Assoc. 2005;293:1737–45.

    Article  CAS  Google Scholar 

  26. Middleton RJ, Parfrey PS, Foley RN. Left ventricular hypertrophy in the renal patient. J Am Soc Nephrol: JASN. 2001;12:1079–84.

    PubMed  CAS  Google Scholar 

  27. Taddei S, Nami R, Bruno RM, Quatrini I, Nuti R. Hypertension, left ventricular hypertrophy and chronic kidney disease. Heart Fail Rev. 2011;16:615–20.

    Article  PubMed  Google Scholar 

  28. • Smith GL, Lichtman JH, Bracken MB, Shlipak MG, Phillips CO, DiCapua P, et al. Renal impairment and outcomes in heart failure: systematic review and meta-analysis. J Am Coll Cardiol. 2006;47:1987–96. This is an excellent meta-analysis that estimated the prevalence of renal impairment in HF patients and the magnitude of associated mortality risk using a systematic review of 16 published studies in 80,098 hospitalized and non-hospitalized HF patients.

    Article  PubMed  Google Scholar 

  29. Hillege HL, Nitsch D, Pfeffer MA, Swedberg K, McMurray JJ, Yusuf S, et al. Renal function as a predictor of outcome in a broad spectrum of patients with heart failure. Circulation. 2006;113:671–8.

    Article  PubMed  Google Scholar 

  30. Jokinen JJ, Tikkanen J, Kukkonen S, Hammainen P, Lommi J, Sipponen J, et al. Natural course and risk factors for impaired renal function during the first year after heart transplantation. J Heart Lung Transplant Off Publ Int Soc Heart Transplant. 2010;29:633–40.

    Article  Google Scholar 

  31. Odim J, Wheat J, Laks H, Kobashigawa J, Gjertson D, Osugi A, et al. Peri-operative renal function and outcome after orthotopic heart transplantation. J Heart Lung Transplant Of Publ Int Soc Heart Transplant. 2006;25:162–6.

    Article  Google Scholar 

  32. Benck U, Hoeger S, Brinkkoetter PT, Gottmann U, Doenmez D, Boesebeck D, et al. Effects of donor pre-treatment with dopamine on survival after heart transplantation: a cohort study of heart transplant recipients nested in a randomized controlled multicenter trial. J Am Coll Cardiol. 2011;58:1768–77.

    Article  PubMed  CAS  Google Scholar 

  33. Gardner RS, Chong KS, O’Meara E, Jardine A, Ford I, McDonagh TA. Renal dysfunction, as measured by the modification of diet in renal disease equations, and outcome in patients with advanced heart failure. Eur Heart J. 2007;28:3027–33.

    Article  PubMed  Google Scholar 

  34. Giamouzis G, Kalogeropoulos AP, Georgiopoulou VV, Agha SA, Rashad MA, Laskar SR, et al. Incremental value of renal function in risk prediction with the Seattle Heart Failure Model. Am Heart J. 2009;157:299–305.

    Article  PubMed  Google Scholar 

  35. • Butler J, Geisberg C, Howser R, Portner PM, Rogers JG, Deng MC, et al. Relationship between renal function and left ventricular assist device use. Ann Thorac Surg. 2006;81:1745–51. This is an excellent study that evaluated the association between baseline renal function and outcomes after LVAD implantation. The authors demonstrated that poor renal function is associated with worse outcomes, and that renal function improves substantially and rapidly in post-LVAD survivors and is associated with improved outcomes.

    Article  PubMed  Google Scholar 

  36. Cowger J, Sundareswaran K, Rogers JG, Park SJ, Pagani FD, Bhat G, et al. Predicting survival in patients receiving continuous flow left ventricular assist devices: the HeartMate II risk score. J Am Coll Cardiol. 2013;61:313–21.

    Article  PubMed  CAS  Google Scholar 

  37. Matthews JC, Koelling TM, Pagani FD, Aaronson KD. The right ventricular failure risk score a pre-operative tool for assessing the risk of right ventricular failure in left ventricular assist device candidates. J Am Coll Cardiol. 2008;51:2163–72.

    Article  PubMed  Google Scholar 

  38. Kormos RL, Teuteberg JJ, Pagani FD, Russell SD, John R, Miller LW, et al. Right ventricular failure in patients with the HeartMate II continuous-flow left ventricular assist device: incidence, risk factors, and effect on outcomes. J Thorac Cardiovasc Surg. 2010;139:1316–24.

    Article  PubMed  Google Scholar 

  39. Heywood JT, Fonarow GC, Costanzo MR, Mathur VS, Wigneswaran JR, Wynne J. High prevalence of renal dysfunction and its impact on outcome in 118,465 patients hospitalized with acute decompensated heart failure: a report from the ADHERE database. J Card Fail. 2007;13:422–30.

    Article  PubMed  Google Scholar 

  40. Cleland JG, Swedberg K, Cohen-Solal A, Cosin-Aguilar J, Dietz R, Follath F, et al. The Euro Heart Failure Survey of the EUROHEART survey programme. A survey on the quality of care among patients with heart failure in Europe. The Study Group on Diagnosis of the Working Group on Heart Failure of the European Society of Cardiology. The Medicines Evaluation Group Centre for Health Economics University of York. Eur J Heart Fail. 2000;2:123–32.

    Article  PubMed  CAS  Google Scholar 

  41. Cleland JG, Swedberg K, Follath F, Komajda M, Cohen-Solal A, Aguilar JC, et al. The EuroHeart Failure survey programme– a survey on the quality of care among patients with heart failure in Europe. Part 1: patient characteristics and diagnosis. Eur Heart J. 2003;24:442–63.

    Article  PubMed  CAS  Google Scholar 

  42. •• Fonarow GC, Adams Jr KF, Abraham WT, Yancy CW, Boscardin WJ. Risk stratification for in-hospital mortality in acutely decompensated heart failure: classification and regression tree analysis. JAMA J Am Med Assoc. 2005;293:572–80. This is an excellent paper in which the authors developed and validated a practical, user-friendly bedside tool for risk stratification for patients hospitalized with ADHF. Using vital sign and laboratory data obtained on hospital admission, the authors could easily identify ADHF patients at low-, intermediate-, and high-risk for in-hospital mortality.

    Article  CAS  Google Scholar 

  43. Lainscak M, Cleland JG, Lenzen MJ, Follath F, Komajda M, Swedberg K. International variations in the treatment and co-morbidity of left ventricular systolic dysfunction: data from the EuroHeart Failure Survey. Eur J Heart Fail. 2007;9:292–9.

    Article  PubMed  Google Scholar 

  44. Lenzen MJ, Scholte op Reimer WJ, Boersma E, Vantrimpont PJ, Follath F, Swedberg K, et al. Differences between patients with a preserved and a depressed left ventricular function: a report from the EuroHeart Failure Survey. Eur Heart J. 2004;25:1214–20.

    Article  PubMed  CAS  Google Scholar 

  45. Adams Jr KF, Fonarow GC, Emerman CL, LeJemtel TH, Costanzo MR, Abraham WT, et al. Characteristics and outcomes of patients hospitalized for heart failure in the United States: rationale, design, and preliminary observations from the first 100,000 cases in the Acute Decompensated Heart Failure National Registry (ADHERE). Am Heart J. 2005;149:209–16.

    Article  PubMed  Google Scholar 

  46. O’Connor CM, Mentz RJ, Cotter G, Metra M, Cleland JG, Davison BA, et al. The PROTECT in-hospital risk model: 7-day outcome in patients hospitalized with acute heart failure and renal dysfunction. Eur J Heart Fail. 2012;14:605–12.

    Article  PubMed  Google Scholar 

  47. Smith GL, Vaccarino V, Kosiborod M, Lichtman JH, Cheng S, Watnick SG, et al. Worsening renal function: what is a clinically meaningful change in creatinine during hospitalization with heart failure? J Card Fail. 2003;9:13–25.

    Article  PubMed  CAS  Google Scholar 

  48. Krumholz HM, Chen YT, Vaccarino V, Wang Y, Radford MJ, Bradford WD, et al. Correlates and impact on outcomes of worsening renal function in patients > or =65 years of age with heart failure. Am J Cardiol. 2000;85:1110–3.

    Article  PubMed  CAS  Google Scholar 

  49. Forman DE, Butler J, Wang Y, Abraham WT, O’Connor CM, Gottlieb SS, et al. Incidence, predictors at admission, and impact of worsening renal function among patients hospitalized with heart failure. J Am Coll Cardiol. 2004;43:61–7.

    Article  PubMed  Google Scholar 

  50. Kociol RD, Greiner MA, Hammill BG, Phatak H, Fonarow GC, Curtis LH, et al. Long-term outcomes of medicare beneficiaries with worsening renal function during hospitalization for heart failure. Am J Cardiol. 2010;105:1786–93.

    Article  PubMed  Google Scholar 

  51. Lucas C, Johnson W, Hamilton MA, Fonarow GC, Woo MA, Flavell CM, et al. Freedom from congestion predicts good survival despite previous class IV symptoms of heart failure. Am Heart J. 2000;140:840–7.

    Article  PubMed  CAS  Google Scholar 

  52. Elkayam U, Hatamizadeh P, Janmohamed M. The challenge of correcting volume overload in hospitalized patients with decompensated heart failure. J Am Coll Cardiol. 2007;49:684–6.

    Article  PubMed  Google Scholar 

  53. Damman K, Ng Kam Chuen MJ, MacFadyen RJ, Lip GY, Gaze D, Collinson PO, et al. Volume status and diuretic therapy in systolic heart failure and the detection of early abnormalities in renal and tubular function. J Am Coll Cardiol. 2011;57:2233–41.

    Article  PubMed  Google Scholar 

  54. Damman K, Voors AA, Hillege HL, Navis G, Lechat P, van Veldhuisen DJ, et al. Congestion in chronic systolic heart failure is related to renal dysfunction and increased mortality. Eur J Heart Fail. 2010;12:974–82.

    Article  PubMed  Google Scholar 

  55. • Metra M, Davison B, Bettari L, Sun H, Edwards C, Lazzarini V, et al. Is worsening renal function an ominous prognostic sign in patients with acute heart failure? The role of congestion and its interaction with renal function. Circ Heart Fail. 2012;5:54–62. This is the first study to evaluate the interaction between WRF and congestion in AHF patients, showing that WRF alone, when detected using serial serum creatinine measurements, is not an independent determinant of outcomes in patients with AHF; it has an additive prognostic value when it occurs in patients with persistent signs of congestion.

    Article  PubMed  Google Scholar 

  56. Aronson D, Abassi Z, Allon E, Burger AJ. Fluid loss, venous congestion, and worsening renal function in acute decompensated heart failure. Eur J Heart Fail. 2013;15:637–43.

    Article  PubMed  CAS  Google Scholar 

  57. Binanay C, Califf RM, Hasselblad V, O’Connor CM, Shah MR, Sopko G, et al. Evaluation study of congestive heart failure and pulmonary artery catheterization effectiveness: the ESCAPE trial. JAMA J Am Med Assoc. 2005;294:1625–33.

    Article  Google Scholar 

  58. Verbrugge FH, Dupont M, Steels P, Grieten L, Malbrain M, Tang WH, et al. Abdominal contributions to cardio-renal dysfunction in congestive heart failure. J Am Coll Cardiol. 2013;62(6):485–95.

    Google Scholar 

  59. Testani JM, Damman K. Venous congestion and renal function in heart failure … it’s complicated. Eur J Heart Fail. 2013;15:599–601.

    Article  PubMed  Google Scholar 

  60. Bishara B, Abu-Saleh N, Awad H, Ghrayeb N, Goltsman I, Aronson D, et al. Phosphodiesterase 5 inhibition protects against increased intra-abdominal pressure-induced renal dysfunction in experimental congestive heart failure. Eur J Heart Fail. 2012;14:1104–11.

    Article  PubMed  CAS  Google Scholar 

  61. Mullens W, Abrahams Z, Francis GS, Taylor DO, Starling RC, Tang WH. Prompt reduction in intra-abdominal pressure following large-volume mechanical fluid removal improves renal insufficiency in refractory decompensated heart failure. J Card Fail. 2008;14:508–14.

    Article  PubMed  Google Scholar 

  62. Mullens W, Abrahams Z, Skouri HN, Francis GS, Taylor DO, Starling RC, et al. Elevated intra-abdominal pressure in acute decompensated heart failure: a potential contributor to worsening renal function? J Am Coll Cardiol. 2008;51:300–6.

    Article  PubMed  Google Scholar 

  63. Balta S, Demirkol S, Arslan Z, Sahin MA, Yesil FG, Kucuk U. The relation between decreased glomerular filtration rate and nonvalvular atrial fibrillation. Cardiology. 2013;124:219.

    Article  PubMed  Google Scholar 

  64. Iguchi Y, Kimura K, Kobayashi K, Aoki J, Terasawa Y, Sakai K, et al. Relation of atrial fibrillation to glomerular filtration rate. Am J Cardiol. 2008;102:1056–9.

    Article  PubMed  Google Scholar 

  65. Goldenberg I, Moss AJ, McNitt S, Zareba W, Andrews ML, Hall WJ, et al. Relations among renal function, risk of sudden cardiac death, and benefit of the implanted cardiac defibrillator in patients with ischemic left ventricular dysfunction. Am J Cardiol. 2006;98:485–90.

    Article  PubMed  Google Scholar 

  66. Saxon LA, Bristow MR, Boehmer J, Krueger S, Kass DA, De Marco T, et al. Predictors of sudden cardiac death and appropriate shock in the Comparison of Medical Therapy, Pacing, and Defibrillation in Heart Failure (COMPANION) Trial. Circulation. 2006;114:2766–72.

    Article  PubMed  Google Scholar 

  67. A comparison of antiarrhythmic-drug therapy with implantable defibrillators in patients resuscitated from near-fatal ventricular arrhythmias. The Antiarrhythmics versus Implantable Defibrillators (AVID) Investigators. N Engl J Med. 1997;337:1576–83.

  68. Herzog CA, Li S, Weinhandl ED, Strief JW, Collins AJ, Gilbertson DT. Survival of dialysis patients after cardiac arrest and the impact of implantable cardioverter defibrillators. Kidney Int. 2005;68:818–25.

    PubMed  Google Scholar 

  69. Hreybe H, Ezzeddine R, Bedi M, Barrington W, Bazaz R, Ganz LI, et al. Renal insufficiency predicts the time to first appropriate defibrillator shock. Am Heart J. 2006;151:852–6.

    Article  PubMed  Google Scholar 

  70. Triposkiadis F, Karayannis G, Giamouzis G, Skoularigis J, Louridas G, Butler J. The sympathetic nervous system in heart failure physiology, pathophysiology, and clinical implications. J Am Coll Cardiol. 2009;54:1747–62.

    Article  PubMed  CAS  Google Scholar 

  71. Triposkiadis F, Giamouzis G, Kelepeshis G, Sitafidis G, Skoularigis J, Demopoulos V. Acute hemodynamic effects of moderate doses of nebivolol versus metoprolol in patients with systolic heart failure. Int J Clin Pharmacol Ther. 2007;45:71–7.

    Article  PubMed  CAS  Google Scholar 

  72. Cohen-Solal A, Kotecha D, van Veldhuisen DJ, Babalis D, Böhm M, Coats AJ, et al. Efficacy and safety of nebivolol in elderly heart failure patients with impaired renal function: insights from the SENIORS trial. Eur J Heart Fail. 2009;11:872–80.

    Article  PubMed  CAS  Google Scholar 

  73. Giamouzis G, Butler J, Starling RC, Karayannis G, Nastas J, Parisis C, et al. Impact of dopamine infusion on renal function in hospitalized heart failure patients: results of the Dopamine in Acute Decompensated Heart Failure (DAD-HF) Trial. J Card Fail. 2010;16:922–30.

    Article  PubMed  CAS  Google Scholar 

  74. Damman K, Voors AA. Levosimendan improves renal function in acute decompensated heart failure: cause and clinical application. Editorial to: “Levosimendan improves renal function in patients with acute decompensated heart failure: comparison with dobutamine by Yilmaz et al.”. Cardiovascular drugs and therapy / sponsored by the International Society of Cardiovascular. Pharmacotherapy. 2007;21:403–4.

    CAS  Google Scholar 

  75. Teerlink JR, Iragui VJ, Mohr JP, Carson PE, Hauptman PJ, Lovett DH, et al. The safety of an adenosine A(1)-receptor antagonist, rolofylline, in patients with acute heart failure and renal impairment: findings from PROTECT. Drug Saf Int J M Toxicol Drug Experience. 2012;35:233–44.

    Article  CAS  Google Scholar 

  76. Gheorghiade M, Konstam MA, Burnett Jr JC, Grinfeld L, Maggioni AP, Swedberg K, et al. Short-term clinical effects of tolvaptan, an oral vasopressin antagonist, in patients hospitalized for heart failure: the EVEREST Clinical Status Trials. JAMA J Am Med Assoc. 2007;297:1332–43.

    Article  CAS  Google Scholar 

  77. Konstam MA, Gheorghiade M, Burnett Jr JC, Grinfeld L, Maggioni AP, Swedberg K, et al. Effects of oral tolvaptan in patients hospitalized for worsening heart failure: the EVEREST Outcome Trial. JAMA J Am Med Assoc. 2007;297:1319–31.

    Article  CAS  Google Scholar 

Download references

Compliance with Ethics Guidelines

Conflict of Interest

Gregory Giamouzis, Andreas P. Kalogeropoulos, Javed Butler, Georgios Karayannis, Vasiliki V. Georgiopoulou, John Skoularigis, Filippos Triposkiadis declare that they have no conflict of interest.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

Author information

Authors and Affiliations

  1. Heart Failure Unit, Cardiology Department, Larissa University Hospital, P.O. Box 1425, 411 10, Larissa, Greece

    Gregory Giamouzis, Georgios Karayannis, John Skoularigis & Filippos Triposkiadis

  2. Division of Cardiology, Emory University, Atlanta, GA, USA

    Andreas P. Kalogeropoulos, Javed Butler & Vasiliki V. Georgiopoulou

  3. Faculty of Medicine, School of Health Sciences, University of Thessaly, Larissa, Greece

    Gregory Giamouzis, John Skoularigis & Filippos Triposkiadis

Authors
  1. Gregory Giamouzis
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Andreas P. Kalogeropoulos
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Javed Butler
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Georgios Karayannis
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Vasiliki V. Georgiopoulou
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. John Skoularigis
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Filippos Triposkiadis
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Gregory Giamouzis.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Giamouzis, G., Kalogeropoulos, A.P., Butler, J. et al. Epidemiology and Importance of Renal Dysfunction in Heart Failure Patients. Curr Heart Fail Rep 10, 411–420 (2013). https://doi.org/10.1007/s11897-013-0164-6

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11897-013-0164-6

Keywords

Search

Navigation